{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-031423","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2026-08-05T20:10:51+00:00","discovered_at":"2026-08-05T20:12:30.200370+00:00","generated_at":"2026-08-05T20:12:39.636328+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ADMA Q2 2026 net income $37.8M (+11% YoY); ASCENIV revenue $102.9M (+24% YoY)","bullets":["Total revenue $124.4M (+2% YoY); GAAP net income $37.8M (+11% YoY); GAAP basic EPS $0.17 (+17% YoY).","ASCENIV revenue $102.9M (+24% YoY); BIVIGAM revenue $19.4M (-49% YoY but sequential improvement from Q1 2026 trough).","Gross margin expanded to 69% from 55% YoY, driven by product mix shift toward higher-margin ASCENIV and yield-enhanced manufacturing.","Adjusted EBITDA $61.8M (+22% YoY); FY2026 guidance reiterated: revenue $530-560M, adj. EBITDA $265-300M.","Repurchased ~7.1M shares in Q2 (13.8M YTD, 5.3% of shares outstanding); SG-001 development on track for pre-IND submission by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-031423","json":"https://secwatch.observer/filing/0001140361-26-031423.json","markdown":"https://secwatch.observer/filing/0001140361-26-031423.md","text":"https://secwatch.observer/filing/0001140361-26-031423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126031423/0001140361-26-031423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126031423/ef20079311_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:12:39.636328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}